Crescent Biopharma, Inc. (CBIO)
Develops cancer-fighting antibody drugs designed to work against multiple tumor targets simultaneously.
$16.44-0.03%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+37.0%
The outlook
CBIO is trading near the lower end of its 52-week range, roughly 41% of the way from its low to high. Analysts collectively rate it a Strong Buy with an average price target implying roughly 89% upside from current levels. Price action remains mixed relative to its moving averages, reflecting near-term uncertainty despite the bullish analyst lean.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 5 analysts
Price trendMixed vs its moving averages
52-week range41% of the way from its 52-week low to high
Price targetAvg target +89% vs current price
Analyst price target
~12-month · 5 analysts$31.00average target+88.6% vs now
Now $16.44
Low $27.00High $35.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$607.7M
52-wk high
$27.41
52-wk low
$8.72
50-day avg
$17.82
200-day avg
$14.80
Trailing P/E
—